ArticleBiomacromolecules2025
Controlling the Sulfation Density of Glycosaminoglycan Glycopolymer Mimetics Enables High Antiviral Activity against SARS-CoV-2 and Reduces Anticoagulant Activity.
Article in Biomacromolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fully Synthetic, Biomimicking Polysulfates With Tunable Anticoagulant and Endothelial Cell-Selective Bioactivity.Macromolecular bioscience · 2026Article
- Protein-Linker Co-engineering for Broad-Spectrum Antiviral Development against Enveloped Viruses.ACS materials letters · 2026Article
- Supramolecular Carbohydrate Assemblies with Tunable Glycan Surfaces.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfated glycosaminoglycans (sGAGs) make up a class of cell-surface glycans known to mediate pathogen engagement. Glycopolymers mimicking sGAGs can reduce or prevent pathogen attachment. However, their high anticoagulant activity limits their biomedical applications. Here, we report the synthesis and evaluation of synthetic glycopolymers mimicking sGAGs with high antiviral activity but low anticoagulant activity. The key lies in the control of the density of carbohydrates presented along the polymeric backbone. This was accomplished via copolymerization of carbohydrate with noncarbohydrate monomers. We reveal that the polymer chain length affects inhibition of SARS-CoV-2 pseudovirus (PsV) and authentic virus infections, and that above a critical chain length, density of carbohydrate and sulfate groups can be reduced, maintaining high antiviral activity while minimizing anticoagulant activity. This demonstrates, for the first time, how specific structural parameters of glycopolymers can be used to maximize inhibition while minimizing anticoagulative properties unlocking the full potential of sGAG mimetics in fighting infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.